1. Apostolakis S, Lip GY, Shantsila E. Pharmacokinetic considerations for antithrombotic therapies in stroke. Expert Opin Drug Metab Toxicol. 2013;9:1335–47.
2. Barnes PJ, Chung KF, Page CP. Inflammatory mediators and asthma. Pharmacol Rev. 1988;40:49–84.
3. Baztán JJ, Pérez-Martínez DA, Fernández-Alonso M, Aguado-Ortego R, Bellando-Alvarez G, de la Fuente-González AM. Prognostic factors of functional recovery in very elderly stroke patients. A one-year follow-up study. Rev Neurol. 2007;44:577–83.
4. Beavo JA. Multiple phosphodiesterase isoenzymes: background, nomenclature, and implications. In: Beavo J, MD H, editors. Cyclic nucleotide phophodiesterases: structure, regulation and drug action, vol. 2. Chichester: Wiley; 1990. p. 3–19.
5. Beglopoulos V, Shen J. Regulation of CRE-dependent transcription by presenilins: prospects for therapy of Alzheimer’s disease. Trends Pharmacol Sci. 2006;27:33–40.